Concordia Healthcare Corp (TSE:CXR)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Monday, StockTargetPrices.com reports. They presently have a C$18.00 price target on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 156.78% from the company’s current price.
A number of other analysts have also recently issued reports on CXR. CIBC cut Concordia Healthcare Corp from a “sector perform” rating to an “underperform” rating in a research report on Monday, August 15th. Goldman Sachs Group Inc. decreased their target price on Concordia Healthcare Corp from C$34.00 to C$17.00 in a research report on Monday, August 15th. Finally, TD Securities decreased their target price on Concordia Healthcare Corp from C$45.00 to C$37.00 and set a “buy” rating for the company in a research report on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Concordia Healthcare Corp currently has an average rating of “Hold” and a consensus target price of C$27.25.
Concordia Healthcare Corp (TSE:CXR) traded down 5.42% during mid-day trading on Monday, hitting $6.63. The stock had a trading volume of 238,489 shares. The firm’s market cap is $338.24 million. The stock has a 50-day moving average price of $11.78 and a 200 day moving average price of $27.51. Concordia Healthcare Corp has a 12-month low of $5.80 and a 12-month high of $28.35.
Concordia Healthcare Corp Company Profile
Receive News & Ratings for Concordia Healthcare Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp and related companies with MarketBeat.com's FREE daily email newsletter.